Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 391

1.

Chemical attributes of soil and growth of castor beans fertilized with drilling gravel from oil wells and castor pie.

Schultz N, Ouverney Leite T, de Andrade Martins Coelho L, Pinheiro Junior CR, Zonta E.

Sci Total Environ. 2019 Aug 1;695:133652. doi: 10.1016/j.scitotenv.2019.133652. [Epub ahead of print]

PMID:
31425995
2.

Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis.

Vedanayagam J, Chatila WK, Aksoy BA, Majumdar S, Skanderup AJ, Demir E, Schultz N, Sander C, Lai EC.

Nat Commun. 2019 Aug 15;10(1):3682. doi: 10.1038/s41467-019-11610-1.

3.

Multispectral Imaging Of Hand Eczema.

Hald M, Thyssen JP, Zachariae C, Røpke MA, Carstensen JM, Schultz N, Johansen JD.

Contact Dermatitis. 2019 Aug 6. doi: 10.1111/cod.13377. [Epub ahead of print]

PMID:
31389010
4.

Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer.

Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA, Schultz N, Janjigian YY, Ku GY.

Clin Cancer Res. 2019 Jul 23. pii: clincanres.3603.2018. doi: 10.1158/1078-0432.CCR-18-3603. [Epub ahead of print]

PMID:
31337644
5.

Exploration of Content and Reach of Physical Therapy-Related Discussion on Twitter.

Sabus C, Johns B, Schultz N, Gagnon K.

Phys Ther. 2019 Aug 1;99(8):1048-1055. doi: 10.1093/ptj/pzz063.

PMID:
31329985
6.

Integration and analysis of CPTAC proteomics data in the context of cancer genomics in the cBioPortal.

Wu P, Heins ZJ, Muller J, Katsnelson L, de Bruijn I, Abeshouse AA, Schultz N, Fenyö D, Gao J.

Mol Cell Proteomics. 2019 Jul 15. pii: mcp.TIR119.001673. doi: 10.1074/mcp.TIR119.001673. [Epub ahead of print]

7.

Tumour lineage shapes BRCA-mediated phenotypes.

Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.

Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10.

PMID:
31292550
8.

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.

Schultz N, Janelidze S, Byman E, Minthon L, Nägga K, Hansson O, Wennström M.

PLoS One. 2019 Jun 17;14(6):e0218561. doi: 10.1371/journal.pone.0218561. eCollection 2019.

9.

Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B.

J Manag Care Spec Pharm. 2019 Aug;25(8):889-897. doi: 10.18553/jmcp.2019.19109. Epub 2019 Jun 7.

10.

Publisher Correction: The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM.

Nat Genet. 2019 Jul;51(7):1194. doi: 10.1038/s41588-019-0451-6.

PMID:
31152158
11.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer.

Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141. [Epub ahead of print]

12.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

13.

Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.

Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang L, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY.

Clin Cancer Res. 2019 Jul 1;25(13):3811-3817. doi: 10.1158/1078-0432.CCR-18-3789. Epub 2019 Apr 5.

PMID:
30952642
14.

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma.

Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, Stirdivant S, Tang J, Schultz N, Jeng P, Dong Y, Su W, Cheng EH, Russo P, Coleman JA, Papaemmanuil E, Chen YB, Reuter VE, Sander C, Kennedy SR, Hsieh JJ, Lyssiotis CA, Tickoo SK, Hakimi AA.

Elife. 2019 Apr 1;8. pii: e38986. doi: 10.7554/eLife.38986.

15.

The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis.

Schultz NH, Holme PA, Henriksson CE, Mowinckel MC, Sandset PM, Bratseth V, Jacobsen EM.

Thromb Res. 2019 May;177:154-156. doi: 10.1016/j.thromres.2019.03.010. Epub 2019 Mar 14. No abstract available.

PMID:
30903875
16.

The expanding landscape of 'oncohistone' mutations in human cancers.

Nacev BA, Feng L, Bagert JD, Lemiesz AE, Gao J, Soshnev AA, Kundra R, Schultz N, Muir TW, Allis CD.

Nature. 2019 Mar;567(7749):473-478. doi: 10.1038/s41586-019-1038-1. Epub 2019 Mar 20.

PMID:
30894748
17.

Differential Role of Cannabis Use Motives in Predicting Impairment Across Three Measures.

Schultz NR, Bassett DT, Messina BG, Correia CJ.

J Stud Alcohol Drugs. 2019 Jan;80(1):26-31.

PMID:
30807271
18.

Evaluation of the psychometric properties of the cannabis use disorders identification test - revised among college students.

Schultz NR, Bassett DT, Messina BG, Correia CJ.

Addict Behav. 2019 Aug;95:11-15. doi: 10.1016/j.addbeh.2019.02.016. Epub 2019 Feb 18.

PMID:
30798191
19.

A Potential Role for α-Amylase in Amyloid-β-Induced Astrocytic Glycogenolysis and Activation.

Byman E, Schultz N; Netherlands Brain Bank, Blom AM, Wennström M.

J Alzheimers Dis. 2019;68(1):205-217. doi: 10.3233/JAD-180997.

PMID:
30775997
20.

Evaluation of an HMGA2 variant for pleiotropic effects on height and metabolic traits in ponies.

Norton EM, Avila F, Schultz NE, Mickelson JR, Geor RJ, McCue ME.

J Vet Intern Med. 2019 Mar;33(2):942-952. doi: 10.1111/jvim.15403. Epub 2019 Jan 21.

21.

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA; AACR Project GENIE Consortium.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083.

22.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801.

PMID:
30589920
23.

Statin treatment before stroke reduces pro-inflammatory cytokine levels after stroke.

Schultz NEØ, Hasseldam H, Rasmussen RS, Vindegaard N, McWilliam O, Iversen HK, Johansen FF.

Neurol Res. 2019 Apr;41(4):289-297. doi: 10.1080/01616412.2018.1558000. Epub 2018 Dec 21.

PMID:
30574850
24.

The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis.

Schultz NH, Holme PA, Bjørnsen S, Henriksson CE, Sandset PM, Jacobsen EM.

Platelets. 2018 Dec 20:1-5. doi: 10.1080/09537104.2018.1557618. [Epub ahead of print]

PMID:
30569801
25.

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S.

Cancer Cell. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006.

PMID:
30537512
26.

The Juvenile Mental Health Advocacy Project for Court-Involved Youths.

Elliott P, Schultz N, Feinberg E.

Psychiatr Serv. 2018 Dec 1;69(12):1268. doi: 10.1176/appi.ps.691201. No abstract available.

PMID:
30501492
27.

Synchronous and metachronous liver metastases in patients with colorectal cancer.

Okholm C, Mollerup TK, Schultz NA, Strandby RB, Achiam MP.

Dan Med J. 2018 Dec;65(12). pii: A5524.

PMID:
30511638
28.

Associations between endocrine disrupting chemicals and equine metabolic syndrome phenotypes.

Durward-Akhurst SA, Schultz NE, Norton EM, Rendahl AK, Besselink H, Behnisch PA, Brouwer A, Geor RJ, Mickelson JR, McCue ME.

Chemosphere. 2019 Mar;218:652-661. doi: 10.1016/j.chemosphere.2018.11.136. Epub 2018 Nov 26.

PMID:
30502704
29.

Heritability of metabolic traits associated with equine metabolic syndrome in Welsh ponies and Morgan horses.

Norton EM, Schultz NE, Rendahl AK, Mcfarlane D, Geor RJ, Mickelson JR, McCue ME.

Equine Vet J. 2019 Jul;51(4):475-480. doi: 10.1111/evj.13053. Epub 2018 Dec 15.

PMID:
30472742
30.

Future Liver Remnant (FLR) Increase in Patients with Colorectal Liver Metastases Is Highest the First Week After Portal Vein Occlusion : FLR Increase in Patients with CRLM Is Highest the First Week After PVO.

Hasselgren K, Sandström P, Røsok BI, Sparrelid E, Lindell G, Larsen PN, Larsson AL, Schultz NA, Björnbeth BA, Isaksson B, Rizell M, Björnsson B.

J Gastrointest Surg. 2019 Mar;23(3):556-562. doi: 10.1007/s11605-018-4031-3. Epub 2018 Nov 21.

31.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
32.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

33.

Change in dominance determines herbivore effects on plant biodiversity.

Koerner SE, Smith MD, Burkepile DE, Hanan NP, Avolio ML, Collins SL, Knapp AK, Lemoine NP, Forrestel EJ, Eby S, Thompson DI, Aguado-Santacruz GA, Anderson JP, Anderson TM, Angassa A, Bagchi S, Bakker ES, Bastin G, Baur LE, Beard KH, Beever EA, Bohlen PJ, Boughton EH, Canestro D, Cesa A, Chaneton E, Cheng J, D'Antonio CM, Deleglise C, Dembélé F, Dorrough J, Eldridge DJ, Fernandez-Going B, Fernández-Lugo S, Fraser LH, Freedman B, García-Salgado G, Goheen JR, Guo L, Husheer S, Karembé M, Knops JMH, Kraaij T, Kulmatiski A, Kytöviita MM, Lezama F, Loucougaray G, Loydi A, Milchunas DG, Milton SJ, Morgan JW, Moxham C, Nehring KC, Olff H, Palmer TM, Rebollo S, Riginos C, Risch AC, Rueda M, Sankaran M, Sasaki T, Schoenecker KA, Schultz NL, Schütz M, Schwabe A, Siebert F, Smit C, Stahlheber KA, Storm C, Strong DJ, Su J, Tiruvaimozhi YV, Tyler C, Val J, Vandegehuchte ML, Veblen KE, Vermeire LT, Ward D, Wu J, Young TP, Yu Q, Zelikova TJ.

Nat Ecol Evol. 2018 Dec;2(12):1925-1932. doi: 10.1038/s41559-018-0696-y. Epub 2018 Oct 29.

34.

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin W, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK.

Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293. Epub 2018 Oct 29.

PMID:
30373752
35.

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M.

Mol Cancer Res. 2019 Feb;17(2):446-456. doi: 10.1158/1541-7786.MCR-18-0440. Epub 2018 Oct 17.

PMID:
30333152
36.

FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.

Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R.

Clin Colorectal Cancer. 2019 Mar;18(1):e39-e52. doi: 10.1016/j.clcc.2018.09.005. Epub 2018 Sep 21.

37.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
38.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

39.

Response to "ALPPS Versus Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastases".

Sandström P, Røsok BI, Sparrelid E, Larsen PN, Larsson AL, Lindell G, Schultz NA, Bjørnbeth BA, Isaksson B, Rizell M, Björnsson B.

Ann Surg. 2019 Jan;269(1):e16-e17. doi: 10.1097/SLA.0000000000003046. No abstract available.

PMID:
30247325
40.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J.

Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008.

PMID:
30205045
41.

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.

Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V.

Adv Ther. 2018 Oct;35(10):1639-1655. doi: 10.1007/s12325-018-0774-1. Epub 2018 Sep 6.

42.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7. Erratum in: BMC Urol. 2018 Oct 1;18(1):84.

43.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

44.

Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.

Elife. 2018 Sep 4;7. pii: e37294. doi: 10.7554/eLife.37294.

45.

Response to Comment on "When Innovation Is Not Enough".

Sandström P, Larsson AL, Björnsson B, Røsok BI, Sparrelid E, Larsen PN, Schultz NA, Björnbeth BA, Lindell G, Isaksson B, Rizell M.

Ann Surg. 2019 Aug;270(2):e36-e37. doi: 10.1097/SLA.0000000000003028. No abstract available.

PMID:
30169399
46.

Investigating best practices of district-wide physical activity programmatic efforts in US schools- a mixed-methods approach.

Economos CD, Mueller MP, Schultz N, Gervis J, Miller GF, Pate RR.

BMC Public Health. 2018 Aug 30;18(1):992. doi: 10.1186/s12889-018-5889-4.

47.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

PMID:
30137196
48.

Cancer After Liver Transplantation in Children and Young Adults: A Population-Based Study From 4 Nordic Countries.

Åberg F, Isoniemi H, Pukkala E, Jalanko H, Rasmussen A, Storm HH, Schultz N, Bennet W, Ekvall N, Ericzon BG, Malenicka S, Tretli S, Line PD, Boberg KM, Østensen A, Karlsen TH, Nordin A.

Liver Transpl. 2018 Sep;24(9):1252-1259. doi: 10.1002/lt.25305.

PMID:
30120902
49.

Correction to: Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW.

Adv Ther. 2018 Sep;35(9):1452. doi: 10.1007/s12325-018-0767-0.

50.

KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.

Cho SJ, Yoon C, Lee JH, Chang KK, Lin JX, Kim YH, Kook MC, Aksoy BA, Park DJ, Ashktorab H, Smoot DT, Schultz N, Yoon SS.

Clin Cancer Res. 2018 Dec 15;24(24):6556-6569. doi: 10.1158/1078-0432.CCR-17-1679. Epub 2018 Aug 14.

PMID:
30108106

Supplemental Content

Loading ...
Support Center